Atopic Dermatitis

The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.

Latest News

Roflumilast cream | Image Credit: © luchschenF-stock.adobe.com
Roflumilast Cream 0.05% Durable, Safe for Younger Pediatric Patients

August 15th 2025

The INTEGUMENT-OLE study is an open-label extension analysis that followed a primary investigation from the phase 3 INTEGUMENT-PED trial, which investigated the efficacy and safety of once-daily roflumilast cream 0.05% for atopic dermatitis in children aged 2 to 5 years.

atopic dermatitis | Image Credit: © wladimir1804-stock.adobe.com
Long-Term Lebrikizumab Provides Sustained Skin Clearance in Atopic Dermatitis

August 5th 2025

FDA approval | Image Credit: Maggie-sora.chatgpt.com
FDA Approves Delgocitinib for Moderate to Severe Hand Eczema

July 24th 2025

Atopic Dermatitis | Image Credit: Veranika-stock.adobe.com
Dupilumab Shows Strong Efficacy in SCORAD-Based AD Assessment

July 14th 2025

Atopic dermatitis | Image Credit: © slobodyan_78-stock.adobe.com
Rezpegaldesleukin Potentially Promising for Atopic Dermatitis

July 8th 2025

Topical Therapies for the Treatment of Atopic Dermatitis: Balancing Safety, Efficacy, and Access

Develop a deeper understanding of the atopic dermatitis (AD) patient journey, explore topical therapies and treatment sequencing advancements, and gain insight regarding the payer’s perspective on AD therapies.

Atopic Dermatitis Payer Perspectives

More News

anatomy image
March 4th 2023

Is Atopic Dermatitis Only a Skin Disease, or Is It Something More?

Keith Loria
A group of dermatologists and dermatology students studied why atopic dermatitis may be related to certain cardiovascular diseases, neuropsychiatric diseases, autoimmune diseases, and obesity.
Image representing pediatric patients
March 1st 2023

AD Improvement Following Combo Therapy Not Affected by Comorbidities

Maggie L. Shaw
Study results presented at this year’s American Academy of Allergy Asthma & Immunology annual meeting displayed dupilumab efficacy in children aged 6 months to 5 years who had atopic dermatitis (AD).
Map of the United States
February 22nd 2023

Eczema Prevalence Varies by Race and Ethnicity, With Overall Increase Seen

Maggie L. Shaw
Investigators compared these outcomes due to limited research in the space, with previous surveys suggesting care disparities.
Image of an expensive price tag
February 15th 2023

Caregiver OOP Costs in AD Higher for Pediatric vs Adult Patients

Maggie L. Shaw
This study investigated the impact atopic dermatitis (AD) has on out-of-pocket (OOP) costs for caregivers of pediatric patients with the chronic skin condition.
Image of a digital reminder
February 11th 2023

Eczema Self-management for Patients, Caregivers Benefits From Online Assistance

Maggie L. Shaw
This exploration of eczema self-management investigated the potential effectiveness of 2 online behavioral interventions, 1 each for young patients and their parents and/or caregivers.
Image of a stethoscope next to a globe
February 8th 2023

Greater Understanding of Eczema’s Prevalence Needed to Improve Treatment, Prevention

Maggie L. Shaw
The authors conducted a subanalysis of data on 100,000-plus children from 3 studies to estimate the global prevalence and severity of eczema; they used linear mixed models to do so.
Image of a highway
February 2nd 2023

AD Progression Adversely Influenced by Outdoor Air Pollution

Maggie L. Shaw
With atopic dermatitis (AD) prevalence increasing around the world, primarily in developing countries, investigators evaluated the potential for pollution to have an impact on development of the chronic skin condition among an adult population.
Image of a doctor and patient talking
January 27th 2023

Guidance for AD Management Refreshed With New Recommendations

Maggie L. Shaw
A team of experts from the United States and Canada performed this systematic review, considering for the first time patient values and preferences for their atopic dermatitis (AD) care.
Image of physician and patient of color
January 24th 2023

ACAAI Report Highlights AD, Allergy Care Disparities and Proposed Solutions

Maggie L. Shaw
Following member surveys, expert interviews, and roundtable discussions, the American College of Allergy, Asthma, and Immunology (ACAAI) has released new recommendations for overcoming care disparities among those who have atopic dermatitis (AD) and food allergies.
Image of atopic skin irritation.
January 17th 2023

Atopic Eczema Significantly Associated With Excessive Scarring in New UK Analysis

Maggie L. Shaw
Using data from the UK Biobank, potential correlations were investigated between excessive skin scarring outcomes arising from comorbidities among 230,000-plus European individuals.
Image of a stressed mother
January 12th 2023

Stress Management Important for Mothers of Pediatric Patients With Atopic Dermatitis

Maggie L. Shaw
The parents of pediatric patients who have atopic dermatitis experience stress just as their children do, and this study investigated how that stress manifests among the parents, comparing outcomes between mothers and fathers.
Image of a brain
January 11th 2023

Eczema Exhibits Potential Protection Against Brain Cancer Development

Maggie L. Shaw
For 2 important reasons—that brain cancer is so aggressive and its risk may be elevated in the presence of certain allergies—investigators of a meta-analysis set out to investigate potential connections between eczema and various brain cancers.
Image of inflamed skin
January 4th 2023

Self-care for Atopic Dermatitis Potentially Feasible as Treatment Intervention

Maggie L. Shaw
With mixed findings from previous studies focused on atopic dermatitis and the use of cognitive behavioral therapy (CBT) as a treatment modality, investigators modified an existing online CBT intervention to account for the lack of clinical psychologists in the dermatological space.
Top 5 atopic dermatitis articles.
December 27th 2022

Top 5 Most-Read Atopic Dermatitis Articles of 2022

Matthew Gavidia
This year’s most-read articles on atopic dermatitis (AD) examined AD as a risk factor for other neurological and attention-deficit conditions and efforts to improve the detection of other comorbid conditions associated with the common skin condition.
urban scene
December 23rd 2022

Study Examines Effect of Biologics on IgE Levels in Urban Settings

AJMC Staff
This study was prompted by recent findings that ultra-low IgE levels (IgE <2.5 kU/L) may be linked with a higher risk of cancers.
Patient with atopic dermatitis.
December 22nd 2022

Adjuvant Baricitinib, Topical Corticosteroids Show Long-term Efficacy in Moderate-to-Severe AD

Matthew Gavidia
Adult patients with moderate-to-severe atopic dermatitis (AD) in the phase 3 BREEZE-AD7 study showed sustained improvement of AD signs and symptoms after 68 weeks with combination treatment of bariticitinib and topical corticosteroids.
Eye.
December 16th 2022

Greater Risk of Cataract Surgery Shown in Patients With Atopic Dermatitis, Allergic Diseases

Matthew Gavidia
Korean patients with allergic diseases, including atopic dermatitis (AD), allergic rhinitis (AR), and asthma, had a higher risk of cataract surgery, and the combination of AD and AR resulted in the highest risk.
Child.
December 9th 2022

Childhood Maltreatment Associated With Atopic Disease

Matthew Gavidia
Patients exposed to childhood maltreatment were at greater risk for developing atopic disease compared with unexposed counterparts, and risk of atopic dermatitis and allergic rhinoconjunctivitis may have been attentuated by misdiagnosis.
Itchy skin.
December 8th 2022

New and Emerging Treatments for Atopic Dermatitis

Carrie Nagorka
Matthew Zirwas, MD, FAAD, associate professor of dermatology at Ohio University in Athens, Ohio provides updates on treatment options for AD at the 2022 SDPA Fall Conference.
Mother and baby.
December 1st 2022

Early Life Antibiotic Exposure Linked With Lower Risk of Atopic Dermatitis

Matthew Gavidia
Early life exposure to antibiotics, particularly during weeks 2, 3, and 4 of life, was associated with a decreased risk of atopic dermatitis development.
Jason Ezra Hawkes, MD, MS, FAAD.
November 24th 2022

Dr Jason Ezra Hawkes on Advances in Clinical Research and Gaps in Knowledge for Atopic Dermatitis

Matthew Gavidia
Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, spoke on how clinical studies in atopic dermatitis (AD) are increasingly investigating topics that remain unknown for disease management, including primary vs secondary failures and AD pathophysiology across different ethnic groups.
Diversity.
November 20th 2022

High Burden of AD, Bacterial Skin Infections Seen in Young Urban-Living Indigenous People

Matthew Gavidia
Urban-living Indigenous children and young people in high-income countries reported a higher likelihood of current and severe symptoms of atopic dermatitis (AD) compared with a non-Indigenous population, as well as a higher incidence of bacterial skin infections.
Jason Ezra Hawkes, MD, MS, FAAD.
November 18th 2022

Dr Jason Ezra Hawkes: Education on Chronic Nature, Subtypes of AD Key in Managing Diverse Patients

Matthew Gavidia
Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, discussed why it is important for dermatologists to educate patients on atopic dermatitis (AD) and keep an open mind on variations in disease presentation by skin color.
Topical calcineurin inhibitor cream.
November 14th 2022

Topical Calcineurin Inhibitors for AD Not Associated With Cancer

Matthew Gavidia
Pimecrolimus and tacrolimus, 2 topical calcineurin inhibitors for the treatment of atopic dermatitis (AD), were not shown to increase the risk of cancer based on moderate-certainty evidence from a systematic review and meta-analysis.
Black patients and doctor.
November 10th 2022

Investigating Real-World Effectiveness of Disease-Modifying Therapies in AD by Skin Type

Matthew Gavidia
Real-world patients with atopic dermatitis with dark skin types showed greater mean reduction in disease severity between baseline and 6 months with dupilumab compared with those with light skin types, whereas no differences were observed regarding severity reduction for methotrexate and ciclosporin.
Climate change
November 4th 2022

Climate Change’s Impact on Skin Disease and Vulnerable Populations

Pearl Steinzor
More than 3 billion people worldwide live within highly vulnerable areas with implications for skin health, according to climate change policy makers.
Jason Ezra Hawkes, MD, MS, FAAD.
October 26th 2022

Dr Jason Ezra Hawkes on Prior Authorization, Clinical Documentation Issues Limiting Atopic Dermatitis Treatment Access

Matthew Gavidia
Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, discussed how prior authorizations and other insurance requirements are limiting treatment access in atopic dermatitis and how dermatologists can help ameliorate these approval issues.
adult person touching skin.
October 25th 2022

Dupilumab Efficacy in AD Not Affected by Age of Disease Onset

Matthew Gavidia
Dupilumab exhibited similarly significant and sustained improvements in atopic dermatitis (AD) signs, symptoms, and quality of life of adult patients with moderate to severe AD, regardless of age of disease onset, compared with placebo.
phone app.
October 17th 2022

Improved Treatment Adherence, Clinical Outcomes Associated With Digital Intervention in Atopic Dermatitis

Matthew Gavidia
A digitally delivered targeted intervention of symptom and trigger education, treatment reminders, lifestyle coaching, and healthy lifestyle support demonstrated significant improvements in treatment adherence and related clinical outcomes among Icelandic patients with atopic dermatitis.
Prolonged Corticosteroid Exposure Associated With Adverse Effects for Patients With Atopic Dermatitis
October 12th 2022

Prolonged Corticosteroid Exposure Associated With Adverse Effects for Patients With Atopic Dermatitis

Julia Bonavitacola
Patients with atopic dermatitis reported that exposure to corticosteroid treatment throughout their lifetime put them at a risk for negative outcomes.
<12345678>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo